Physician profile
Amanda Roeding
NPI 1528469160
$10,172.66
in general payments reported to CMS, 2019-2025
66 companies · $2,852 in 2025
The $2,852 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,091 · 2022: $1,498 · 2023: $2,290 · 2024: $2,442 · 2025: $2,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,583.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $730.72 | 2022-2025 | |
| Janssen Biotech, INC. | $670.92 | 2021-2025 | Darzalex, Tecvayli, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $665.56 | 2021-2025 | Calquence, Imfinzi, Lynparza |
| Genzyme Corporation | $545.57 | 2021-2025 | |
| Pfizer INC. | $515.50 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $504.60 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $488.48 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $451.38 | 2021-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $444.77 | 2021-2025 | Opdivo, Krazati, Augtyro |
| Regeneron Healthcare Solutions, INC. | $399.01 | 2022-2025 | Libtayo |
| Glaxosmithkline, LLC. | $330.69 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $318.55 | 2023-2025 | |
| Lilly USA, LLC | $253.86 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $249.60 | 2022-2025 | Alunbrig, Fruzaqla |
| Seagen INC. | $240.63 | 2021-2023 | Adcetris, Tukysa, Tivdak |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $234.58 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $229.58 | 2022-2025 | |
| Puma Biotechnology, INC. | $204.45 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $200.28 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $155.34 | 2022-2025 | Somatuline Depot, Onivyde |
| Amgen INC. | $144.24 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Array Biopharma INC | $110.48 | 2023-2024 | Mektovi, Lorbrena, Braftovi |
| Agios Pharmaceuticals, INC. | $110.22 | 2023-2025 | Pyrukynd |
| Genentech USA, INC. | $99.99 | 2022-2023 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $98.96 | 2021-2023 | Imbruvica |
| Tersera Therapeutics LLC | $97.25 | 2022-2025 | Xermelo, Zoladex |
| Astellas Pharma US INC | $96.32 | 2021-2025 | Vyloy, Xtandi, Xospata |
| Legend Biotech USA INC. | $90.09 | 2025 | Carvykti |
| Sobi, INC | $88.83 | 2022-2025 | |
| Eisai INC. | $87.95 | 2021-2024 | |
| Celgene Corporation | $84.27 | 2023-2025 | Reblozyl |
| Stemline Therapeutics INC. | $83.94 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $81.41 | 2024-2025 | Ogsiveo |
| Taiho Oncology, INC. | $76.09 | 2021-2025 | |
| Blueprint Medicines Corporation | $71.57 | 2021-2023 | Ayvakit |
| Geron Corporation | $65.37 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $62.96 | 2021-2025 | Fotivda |
| Kite Pharma, INC. | $57.96 | 2023-2025 | Yescarta |
| Mirati Therapeutics, INC. | $57.40 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $51.22 | 2021-2024 | |
| Emd Serono, INC. | $44.68 | 2024-2025 | |
| G1 Therapeutics, INC. | $44.65 | 2022-2023 | Cosela |
| Genmab U.S., INC. | $41.77 | 2023 | Epkinly |
| Deciphera Pharmaceuticals INC. | $41.05 | 2021 | |
| Syndax Pharmaceuticals, INC. | $40.36 | 2025 | |
| Pharmaessentia USA Corporation | $39.35 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $33.58 | 2024 | Ultomiris |
| Recordati_rare_diseases_inc. | $33.37 | 2025 | Enjaymo |
| Adc Therapeutics America, INC. | $29.61 | 2022-2023 | |
| Kyowa Kirin, INC. | $28.25 | 2021 | |
| Beone Medicines USA, INC. | $27.13 | 2025 | Tevimbra |
| Sanofi-Aventis U.S. LLC | $23.04 | 2021 | |
| Morphosys, US INC. | $17.50 | 2023 | Monjuvi |
| Exelixis INC. | $17.45 | 2022 | |
| Acceleron Pharma, INC. | $17.15 | 2021 | |
| Cti Biopharma Corp. | $16.12 | 2023 | Vonjo |
| Ge Healthcare | $15.73 | 2022 | |
| Dendreon Pharmaceuticals LLC | $14.49 | 2023 | Provenge |
| Rigel Pharmaceuticals, INC. | $14.13 | 2022 | |
| Sumitomo Pharma America, INC. | $14.10 | 2023 | Orgovyx |
| Myovant Sciences INC. | $13.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.55 | 2023 | Xarelto |
| Pharmacosmos Therapeutics INC. | $12.91 | 2023 | Monoferric |
| Epizyme, INC. | $12.74 | 2021 | |
| Myriad Genetic Laboratories, INC. | $11.44 | 2022 | |
| Adma Biomanufacturing LLC | $4.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Roeding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.